Since osteosarcoma cells overexpress NK-1R, the use of an NK-1R antagonist, aprepitant, could counteract glucose production in osteosarcoma cells, thus preventing the Warburg effect in osteosarcoma cells. Here, TACR1 is linked to osteosarcoma.